N6-甲基腺苷在前列腺癌的发病机制、诊断和治疗中的作用(综述)。

IF 3.8 3区 医学 Q2 ONCOLOGY Oncology reports Pub Date : 2024-06-01 Epub Date: 2024-05-17 DOI:10.3892/or.2024.8747
Junjie Pan, Fei Tong, Ning Ren, Lanqi Ren, Yibei Yang, Feng Gao, Qiaoping Xu
{"title":"N6-甲基腺苷在前列腺癌的发病机制、诊断和治疗中的作用(综述)。","authors":"Junjie Pan, Fei Tong, Ning Ren, Lanqi Ren, Yibei Yang, Feng Gao, Qiaoping Xu","doi":"10.3892/or.2024.8747","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle‑aged males between the ages of 45 and 60 years, and is the highest cause of cancer‑associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N<sup>6</sup>‑methyladenosine (m<sup>6</sup>A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m<sup>6</sup>A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m<sup>6</sup>A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m<sup>6</sup>A methylation modification in PCa. It is considered that the treatment of PCa with micro‑molecular drugs that target the epigenetics of the m<sup>6</sup>A regulator to correct abnormal m<sup>6</sup>A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.</p>","PeriodicalId":19527,"journal":{"name":"Oncology reports","volume":"51 6","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110010/pdf/","citationCount":"0","resultStr":"{\"title\":\"Role of N<sup>6</sup>‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).\",\"authors\":\"Junjie Pan, Fei Tong, Ning Ren, Lanqi Ren, Yibei Yang, Feng Gao, Qiaoping Xu\",\"doi\":\"10.3892/or.2024.8747\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle‑aged males between the ages of 45 and 60 years, and is the highest cause of cancer‑associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N<sup>6</sup>‑methyladenosine (m<sup>6</sup>A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m<sup>6</sup>A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m<sup>6</sup>A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m<sup>6</sup>A methylation modification in PCa. It is considered that the treatment of PCa with micro‑molecular drugs that target the epigenetics of the m<sup>6</sup>A regulator to correct abnormal m<sup>6</sup>A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.</p>\",\"PeriodicalId\":19527,\"journal\":{\"name\":\"Oncology reports\",\"volume\":\"51 6\",\"pages\":\"\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11110010/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncology reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3892/or.2024.8747\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/5/17 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncology reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3892/or.2024.8747","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

前列腺癌(PCa)影响所有种族和民族的男性,由于发现较晚,社会经济地位较低的男性死亡率较高。PCa 主要影响 45 至 60 岁的中年男性,是西方国家癌症相关死亡率最高的原因。N6-甲基腺苷(m6A)是高等真核生物中最丰富、最常见的mRNA修饰,广泛分布于哺乳动物细胞中,影响着mRNA代谢的各个方面。最近的研究发现,各种 m6A 调节因子的异常表达水平会显著影响包括 PCa 在内的各种癌症的发生和发展。本综述基于 PCa 中 m6A 甲基化修饰的研究现状,讨论了 m6A 调控因子通过 mRNA 修饰对 PCa 发病和进展的影响。认为以m6A调节因子表观遗传学为靶点的微分子药物治疗PCa以纠正异常的m6A修饰是目前PCa诊断和治疗方法的一个未来研究方向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).

Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle‑aged males between the ages of 45 and 60 years, and is the highest cause of cancer‑associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N6‑methyladenosine (m6A) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism. Recent studies have found that abnormal expression levels of various m6A regulators significantly affect the development and progression of various types of cancer, including PCa. The present review discusses the influence of m6A regulatory factors on the pathogenesis and progression of PCa through mRNA modification based on the current state of research on m6A methylation modification in PCa. It is considered that the treatment of PCa with micro‑molecular drugs that target the epigenetics of the m6A regulator to correct abnormal m6A modifications is a direction for future research into current diagnostic and therapeutic approaches for PCa.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncology reports
Oncology reports 医学-肿瘤学
CiteScore
8.50
自引率
2.40%
发文量
187
审稿时长
3 months
期刊介绍: Oncology Reports is a monthly, peer-reviewed journal devoted to the publication of high quality original studies and reviews concerning a broad and comprehensive view of fundamental and applied research in oncology, focusing on carcinogenesis, metastasis and epidemiology.
期刊最新文献
[Corrigendum] Tripartite motif‑containing 11 regulates the proliferation and apoptosis of breast cancer cells. [Retracted] Glutathione peroxidase 2 overexpression promotes malignant progression and cisplatin resistance of KRAS‑mutated lung cancer cells. [Retracted] Stimulation of peroxisome proliferator‑activated receptor γ inhibits estrogen receptor α transcriptional activity in endometrial carcinoma cells. Compression force promotes glioblastoma progression through the Piezo1‑GDF15‑CTLA4 axis. Huaier promotes sensitivity of colorectal cancer to oxaliplatin by inhibiting METTL3 to regulate the Wnt/β‑catenin signaling pathway.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1